Short-term Treatment with Dabigatran Alters Protein Expression Patterns in a Late-Stage Tau-Based Alzheimer\u27s Disease Mouse Model by Iannucci, Jaclyn et al.
University of Rhode Island 
DigitalCommons@URI 
Biomedical and Pharmaceutical Sciences 
Faculty Publications Biomedical and Pharmaceutical Sciences 
11-2020 
Short-term Treatment with Dabigatran Alters Protein Expression 
Patterns in a Late-Stage Tau-Based Alzheimer's Disease Mouse 
Model 
Jaclyn Iannucci 
Shelby L. Johnson 
Mark Majchrzak 
University of Rhode Island, mark_majchrzak@uri.edu 
Benjamin J. Barlock 
Fatemeh Akhlaghi 
University of Rhode Island, fakhlaghi@uri.edu 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs 
Citation/Publisher Attribution 
Iannucci J, Johnson SL, Majchrzak M, Barlock BJ, Akhlaghi F, Seeram NP, Sen A, Grammas P. Short-term 
treatment with dabigatran alters protein expression patterns in a late-stage tau-based Alzheimer's disease 
mouse model. Biochem Biophys Rep. 2020 Nov 19;24:100862. doi: 10.1016/j.bbrep.2020.100862. PMID: 
33294639; PMCID: PMC7689047. 
This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at 
DigitalCommons@URI. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty 
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact 
digitalcommons@etal.uri.edu. 
Authors 
Jaclyn Iannucci, Shelby L. Johnson, Mark Majchrzak, Benjamin J. Barlock, Fatemeh Akhlaghi, Navindra P. 
Seeram, Abhik Sen, and Paula Grammas 
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/222 
Biochemistry and Biophysics Reports 24 (2020) 100862
Available online 19 November 2020
2405-5808/© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Short-term treatment with dabigatran alters protein expression patterns in 
a late-stage tau-based Alzheimer’s disease mouse model 
Jaclyn Iannucci a,b,*,1, Shelby L. Johnson a,c,1, Mark Majchrzak a, Benjamin J. Barlock d, 
Fatemeh Akhlaghi d, Navindra P. Seeram a,c, Abhik Sen a, Paula Grammas a,b 
a George & Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI, 02881, USA 
b Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA 
c Bioactive Botanical Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 
02881, USA 
d Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 
02881, USA   






A B S T R A C T   
Proteins that regulate the coagulation cascade, including thrombin, are elevated in the brains of Alzheimer’s 
disease (AD) patients. While studies using amyloid-based AD transgenic mouse models have implicated thrombin 
as a protein of interest, the role of thrombin in tau-based animal models has not been explored. The current study 
aims to determine how inhibiting thrombin could alter oxidative stress, inflammation, and AD-related proteins in 
a tau-based mouse model, the Tg4510. Aged Tg4510 mice were treated with the direct thrombin inhibitor 
dabigatran or vehicle for 7 days, brains collected, and western blot and data-independent proteomics using mass 
spectrometry with SWATH-MS acquisition performed to evaluate proteins related to oxidative stress, intracel-
lular signaling, inflammation, and AD pathology. Dabigatran reduced iNOS, NOX4, and phosphorylation of tau 
(S396, S416). Additionally, dabigatran treatment increased expression of several signaling proteins related to cell 
survival and synaptic function. Increasing evidence supports a chronic procoagulant state in AD, highlighting a 
possible pathogenic role for thrombin. Our data demonstrate that inhibiting thrombin produces alterations in the 
expression of proteins involved in oxidative stress, inflammation, and AD-related pathology, suggesting that 
thrombin-mediated signaling affects multiple AD-related pathways providing a potential future therapeutic 
target.   
1. Introduction 
Cardiovascular disease and cardiovascular risk factors (CVRFs) are 
strongly associated with an increased risk of developing dementia, 
particularly Alzheimer’s disease (AD) [1]. While the connection be-
tween CVRFs and AD is well-documented, mechanisms whereby these 
risk factors confer elevated AD risk have not been delineated. It is likely 
that one or more pathological mediators involved in the progression of 
cardiovascular diseases contributes to AD pathology. The multifunc-
tional protease thrombin is implicated in the development of athero-
sclerosis and diabetes, and more recently suggested as a novel mediator 
in AD [2,3]. 
Thrombin is a pleiotropic enzyme that triggers a large and diverse 
number of cellular events, largely through activation of protease- 
activated receptors (PARs) [4]. Recent evidence indicates that coagu-
lation proteins, including thrombin, also mediate oxidative stress and 
neuroinflammation, invariant features of neurodegenerative diseases 
[5]. To that end, thrombin increases NADPH-dependent superoxide 
anion and hydrogen peroxide production, and injures neurons via 
microglial release of nitric oxide (NO) [6,7]. In a primarily 
amyloid-based AD mouse model (3xTgAD), we have previously shown 
that administration of the thrombin inhibitor dabigatran significantly 
decreases expression of reactive oxygen species (ROS) and inflammatory 
proteins in these mice [8]. 
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There is evidence that thrombin is relevant for AD pathology. Spe-
cifically, thrombin is expressed in AD-derived, but not control brain 
microvessels [9], and the thrombin inhibitor protease nexin-1 is reduced 
in the perivascular space, suggesting that vascular-derived thrombin is 
increased [10]. Levels of both thrombin and the thrombin receptor 
PAR-1 are elevated in AD [11]. Thrombin accumulation has also been 
identified in neurofibrillary tangles, and signaling through the thrombin 
receptor induces tau aggregation and related hippocampal degeneration 
[12]. Thrombin’s role as a pathological mediator in a tau-based AD 
model has not yet been explored. Currently, several tauopathy animal 
models are being used to study AD, including Tg4510, which over-
expresses human tau with a P301L mutation at 13:1 versus murine tau 
[13]. These mice exhibit profound tau pathology and neuronal loss in 
the hippocampus and cortex, as well as cognitive deficits and metabolic 
changes that progress with age [14]. Tg4510 mice also display blood 
vessel abnormalities accompanied by alterations in oxidative and in-
flammatory markers [15]. 
Data linking thrombin to oxidative and inflammatory stress as well 
as tau-related pathology suggest that thrombin could be a target for 
therapeutic intervention in AD. The objective of the current study is to 
investigate the potential therapeutic benefits of inhibiting thrombin in a 
tau-based animal model of AD. In this pilot study, we explore the effects 
of short-term treatment with direct thrombin inhibitor, dabigatran 
etexilate, in aged Tg4510 mice. We hypothesize that inhibiting thrombin 
will reduce oxidative stress and inflammation-related indicators corre-
sponding to an overall reduction in AD-related pathology in the brain. 
2. Materials and methods 
2.1. Animals and treatment 
Female transgenic Tg4510 AD mice (PF/CamKII-tTA Tg 129 x tetO- 
MAPT(P301L) Tg (TG2510 TG/TG)) overexpressing human mutant tau 
(P301L) and background matched controls (PF/CamKII-tTA Tg 129 x 
tetO-MAPT(P301L) Tg-3 (TG2510 WT/WT)) were a kind gift from 
MindImmune Therapeutics, Inc. originally obtained from Charles River 
(Wilmington, MA). Mice were maintained on normal chow (ENVIGO 
2020X, Huntingdon, UK) with water available ad libitum. At 15 months 
of age, mice were treated via oral gavage with vehicle (2.5% DMSO, 
2.5% koliphor EL, 90% diH2O) or dabigatran etexilate (100 mg/kg in 
uniform suspension, Cayman Pharm, Ann Arbor, MI) daily for 7 days 
(n≥4), and then euthanized. All animal procedures were performed in 
accordance with NIH “Guide for the Care and Use of Laboratory Ani-
mals” and University of Rhode Island Institutional Animal Care and Use 
Committee (IACUC) guidelines. 
2.2. Western blot 
Whole brains minus the cerebellum were homogenized by sonication 
(Branson SX150 Sonifier ®, Branson Ultrasonics, Danbury, CT) in 
phosphate buffered saline (PBS) with protease inhibitors. Samples were 
resolved in 4–20% poly-acrylamide gel and transferred to nitrocellulose 
membrane. Membranes were blocked using antibody-specific concen-
tration of Bovine Serum Albumin (BSA) or Milk in Tris-buffered saline +
Tween (TBS-T). Primary antibodies for this study include NOX4 (Sigma, 
MA; 1:1000), iNOS (Abcam, MA; 1:250), and β-Actin (Santa Cruz, CA; 
1:10,000). Tau and p-tau species were detected using phosphor-tau 
family antibody sampler kit (Cell Signaling, MA; 1:500). Bound anti-
body was detected with infrared secondary antibodies (Li-COR Bio-
sciences, Lincoln, NE). Membranes were imaged using LiCor Odyssey 
(LI-COR Biosciences, Lincoln, NE), and quantification was done in 
ImageJ. Values for each protein were normalized to β-actin loading 
control on the same blot. 
2.3. Pressure cycling technology-based protein digestion 
Whole brain homogenates were digested using pressure cycling 
technology (PCT) for LC-MS/MS SWATH acquisition following the 
previously published method with slight modifications [16]. 500 μg of 
protein sample was spiked with 2 ng of BSA and incubated with 
dithiothreitol (100 mM) at 90 ◦C for 15 min, with shaking. Iodoaceta-
mide (200 mM) was added and samples were incubated at room tem-
perature in the dark for 30 min. Protein was then precipitated using 
ice-cold chloroform, methanol, and water (1:2:1) followed by centrifu-
gation at 13,400 xG for 5 min at 10 ◦C. The protein pellet was rinsed 
with methanol and resuspended in 3% w/v sodium deoxycholate (DOC) 
in 50 mM ammonium bicarbonate. Samples were placed in MicroTubes 
(Pressure BioSciences Inc, South Easton, MA) with trypsin at a 1:20 ratio 
of trypsin:protein. Digestion was performed at 55 ◦C for 75 cycles (50 s 
at 35kpsi, 10 s at ambient pressure) in a Barocycler NEP2320-45k 
(Pressure BioSciences Inc). A second digestion was performed by add-
ing fresh trypsin at the same ratio for an additional 60 cycles. Digestion 
was stopped and DOC was precipitated by the addition of formic acid in 
acetonitrile at a final percentage of 0.5%. Samples were centrifuged and 
supernatant was collected for analysis. 
2.4. Data independent proteomics using mass spectrometry with SWATH- 
MS acquisition 
Mass spectrometry was performed as previously described with 
minor modifications [16,17]. Samples were analyzed on a SCIEX Tri-
pleTOF® 5600 mass spectrometer using a DuoSpray™ ion source 
(SCIEX, Framingham, MA) coupled to an Acquity HClass UHPLC system 
(Waters Corp., Milford, MA). Separation was achieved on an Acquity 
UPLC Peptide BEH C18 column (2.1 x 150 mm, 300 Å, 1.7 μm) with an 
Acquity VanGuard pre-column (2.1 x 5 mm, 300 Å, 1.7 μm). The column 
temperature was set to 50 ◦C and the autosampler was set to 10 ◦C. 
Mobile phase A consisted of 99.9% acetonitrile and 0.1% formic acid. 
Mobile phase B consisted of 99.9% water and 0.1% formic acid. A linear 
gradient was used with a flow rate of 100 μL/min for 90 min, as pre-
viously published [17]. A mixture of trypsin-digested β-galactosidase 
peptides were used between every 8 samples to calibrate masses and 
monitor the TOF detector. 
Positive ionization mode was used for data dependent acquisition. 
The mass spectrometer parameters are as follows: gas 1, gas 2, curtain 
gas, temperature and ion spray voltage floating were 55 psi, 60 psi, 25 
psi, 450 ◦C, 5500 V, Respectively. Declustering potential was 10, colli-
sion energy 10 and collision energy spread 15. For data acquisition, a 
maximum of 50 candidate ions were monitored for each survey scan. All 
ions had a charge state from 2 to 4. A range of m/z 300–1250 was used 
for exclusion criteria and all ions that had an intensity greater than 25 
cps were chosen for MS/MS analysis. The temperature was set at 450 ◦C 
and the total cycle time was 3.5 s with a mass tolerance of 50 mDa 
during the first 0.75 s survey scan. 
For SWATH analysis, all parameters were the same as above except 
for the following: Seventy SWATH windows per cycle were collected 
over m/z 400–1100 with each window size being m/z 10 and TOF 
masses were collected from m/z 300 to 1500. 
2.5. Mass spectrometry data analysis 
LC-MS/MS SWATH data was used to generate spectral libraries 
through ProteinPilot (SCIEX, Framingham, MA). FASTA files for pro-
teins of interest were downloaded from UniProt [18] and imported into 
Skyline (MacCoss Lab, University of Washington). In Skyline, at least 3 
transitions were selected per peptide, and at least 3 peptides per protein 
were chosen. Once data was analyzed, the MPPreport (MacCoss Lab, 
University of Washington) was generated and exported to Excel. In 
Excel, transitions were averaged, and the sum of each peptide was 
calculated to yield the total area under the curve representative of each 
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protein. These were then standardized to internal standard, BSA. 
2.6. Statistical analysis 
Data from each experiment are expressed as mean ± standard error 
(SEM), unless otherwise indicated. All tests were performed in GraphPad 
Prism (version 8.0). For Western blot, data were analyzed for signifi-
cance using one-way analysis of variance (ANOVA) and multiple com-
parisons carried out using the post-hoc Bonferroni test. For ratio of 
phosphorylated tau to total tau, student’s t-test was used to determine 
statistical differences. For LC-MS/MS SWATH data, multiple t-tests were 
used to determine statistical differences. Statistical significance was 
determined at p < 0.05. Significance for all tests was defined as follows: 
p ≤ 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
3. Results & discussion 
Increasing evidence has shown that thrombin, and thrombin-related 
proteins are elevated in the brains of AD patients [11]. Furthermore, 
studies using amyloid-based AD transgenic mice models have implicated 
thrombin as a protein of interest [8,19]. Although thrombin accumula-
tion is co-localized with tau aggregation [20], thrombin’s potential role 
in tau-based animal models has not been explored. In the current pilot 
study, we examined how inhibiting thrombin may alter tau-related 
pathologic processes. 
Oxidative stress resulting from generation of high levels of ROS in AD 
is associated with neuron injury, Aβ accumulation, and tau phosphory-
lation [21,22]. A meditator of several physiologic functions, NO is a 
pathological mediator in the brain when continuously produced [22], 
and increased NO and inducible nitric oxide synthase (iNOS) iNOS have 
been documented in AD models [23,24]. Another source of noxious ROS 
in the brain is NADPH oxidase (NOX), a family of enzymes that directly 
regulate ROS production [25]. There is growing evidence that the iso-
forms NOX1, NOX2, and NOX4 are upregulated in a variety of neuro-
degenerative disease. Here, we evaluate the expression of both iNOS and 
NOX4 by western blot (Fig. 1A). The expression of iNOS was signifi-
cantly different across groups (F = 8.175, p < 0.01). iNOS expression 
was significantly (p < 0.01) elevated in Tg4510 mice compared to wild 
type, and treatment of Tg4510 mice with dabigatran significantly (p <
0.05) reduced expression by 17.4% (Fig. 1B). Dabigatran treatment also 
significantly modified the expression of NOX4 across groups (F = 6.305, 
p < 0.05). Dabigatran treatment significantly (p < 0.01) reduced NOX4 
expression by 24.7% compared to untreated Tg4510 mice (Fig. 1C). 
Together, these findings suggest that dabigatran reduces oxidative stress 
through reduction in enzyme expression. 
In order to investigate the effect of dabigatran treatment on tau- 
related pathology, total tau and phosphorylated forms of tau S396 and 
S416 were evaluated by western blot (Fig. 2). The expression of total tau 
(F = 9.942, p < 0.01), S396 (F = 26.78, p < 0.001), and S416 (F = 11.67, 
p < 0.0015) was significantly different across groups. Tg4510 mice 
expressed 75.9% more total tau than wild type mice (p < 0.001). 
Expression of both phosphorylated tau species S396 and S416 was 
significantly (p < 0.001) elevated in Tg4510 mice compared to levels in 
wild type mice. Treatment of Tg4510 mice with dabigatran significantly 
(p < 0.05) lowered levels of both S396 (Fig. 2B) and S416 (Fig. 2C). 
Furthermore, dabigatran treatment significantly (p < 0.05) reduced the 
ratio of phosphorylated tau to total tau for both S396 and S416 
(Table 1). S396 phosphorylation is found early in the disease course of 
AD [26] and is related to destabilization of microtubules [27]. Phos-
phorylation at S416 is largely found within the neuronal soma and has 
been associated with the promotion of AD-related cell death [28]. 
Together, our findings indicate that dabigatran etexilate treatment may 
reduce AD-related tau dysfunction through reduced phosphorylation. 
LC-MS/MS SWATH analysis of all three treatment groups was un-
dertaken based on proteins relevant for AD-related pathological pro-
cesses as well as thrombin/dabigatran-related mechanisms including 
proteins involved in the coagulation cascade, cell signaling, inflamma-
tion, and AD. Protein sequences were obtained from the UniProt data-
base and results from LC-MS/MS with SWATH acquisition were 
analyzed in Skyline, an open source software for targeted proteomics 
(Table 2). Significant differences in protein expression between wild 
type and Tg4510 mice were identified and visualized with a volcano plot 
(Fig. 3A). Further LC-MS/MS SWATH analysis was conducted to deter-
mine differences in protein expression as a result of dabigatran 
Fig. 1. Dabigatran reduces expression of oxidative stress-related proteins in Tg4510 mouse brains. Brain homogenates from wild type mice, Tg4510 mice (Tg- 
Vehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) were analyzed by western blot (A) for iNOS (B) and NOX4 (C). Mean ± SEM (n = 4), significance 
determined by one-way ANOVA with post-hoc Bonferroni, **p ≤ 0.01 vs. Wild Type, #p < 0.05 vs. Tg-Vehicle, ##p < 0.01 vs. Tg-Vehicle. 
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treatment in the Tg4510 mice, visualized with a volcano plot (Fig. 3B). 
Significant differences were detected in coagulation proteins (ANT3, 
FIBB, ITB2, and THRB) (Fig. 4A), cell signaling-related proteins (DYN1, 
KPCB, MK08, MP2K1, MP2K2, and RACK1) (Fig. 4B), and proteins 
related to inflammation (COX2, GFAP, and ICAM5) (Fig. 4C). 
Dabigatran treatment significantly increased the levels of a number 
of cell signaling-related proteins (Fig. 4B). Literature implicates 
dysfunctional MAPK in neurodegenerative diseases, especially AD. Here, 
the MAPK-related proteins MP2K1 and MP2K2 were reduced in Tg4510 
compared to wild type, and significantly elevated in the brains of 
dabigatran treated Tg4510 mice compared to vehicle. MP2K1 and 
MP2K2 are responsible for the activation of the ERK signaling pathway, 
thought to regulate mechanisms of cell growth, differentiation, and 
survival [29]. Dabigatran treatment also increased expression of MK08 
(JNK1), which is involved in both neuronal degeneration and regener-
ation, as well as autophagy [30]. Additionally, dabigatran treatment 
increased expression of dynamin-1 (DYN1), a protein shown to be 
essential for synaptic vesicle recycling and, hence, for memory forma-
tion and information processing [31]. The relationship of both MK08 
and DYN1 to autophagy and organelle recycling suggests these path-
ways should be further explored in light of the literature showing that 
autophagosome-lysosomal degradation is impaired and AD [32]. 
Fig. 2. Dabigatran diminishes levels of phosphorylated tau species in Tg4510 mice. Brain homogenates from wild type mice, Tg4510 mice (Tg-Vehicle), and 
Tg4510 mice treated with dabigatran (Tg-Dabigatran) were analyzed by western blot for total tau (A) tau S396 (B) and tau S416 (C). Mean ± SEM (WT n = 5, Tg- 
Vehicle n = 6, Tg-Dabigatran n = 4), significance determined one-way ANOVA with post-hoc Bonferroni, ***p < 0.001 vs. Wild Type, #p ≤ 0.05 vs. Tg-Vehicle. 
Table 1 
Ratio of phosphorylated tau to total tau is decreased in Tg4510 mice 
treated with dabigatran. Brain homogenates from Tg4510 mice (Tg-Vehicle), 
and Tg4510 mice treated with dabigatran (Tg-Dabigatran) were analyzed by 
western blot for total tau, tau S396, and tau S416. The ratio of phosphorylated 
tau to total tau was calculated for S396 and S416. Values presented as Mean ±
SEM. Significance was determined by student’s t-test, *p ≤ 0.05.  
Tau phosphorylation 
site 











0.0103 (*)  
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Finally, dabigatran treatment increased the level of PKC-β (KPCB), 
which has been implicated as a critical enzyme in learning and memory 
function [33]. Elevation of PKC-β is consistent with the increase in 
DYN1, suggesting that future, long-term studies probing the cognitive 
effects of dabigatran in this AD model are warranted. 
To examine AD-related pathology, we performed LC-MS/MS SWATH 
analysis on a variety of AD-related proteins. A number of classically 
studied AD-related proteins demonstrated significant differences be-
tween wild type and Tg4510 mice, including ApoE, BACE1, TAU 
(Human), TAU (Mouse), and TAU (total) (Fig. 5A). To further explore 
AD-related pathology, we performed LC-MS/MS SWATH analysis on a 
variety of proteins previously found to be altered in sporadic AD and tau 
pathology, identified through literature review [34]. Here, G6PD1, 
HPCA, KCC2A, and VIME were found to be significantly different in 
Tg4510 mice as compared to wild type (Fig. 5B). Dabigatran treatment 
increased the levels of HPCA and KCC2A to roughly those found in wild 
type mice. Furthermore, ANS1B, NCKP1, SV2B, and SYGP were signif-
icantly increased with dabigatran treatment (Fig. 5B). In a previous 
report analyzing tau pathology in human AD brains, these proteins were 
found to be significantly downregulated in late-stage AD [34]. ANS1B 
(Ankyrin repeat and sterile alpha motif domain-containing protein 1B) is 
a scaffold protein localized to the post-synaptic density with an identi-
fied role in facilitating long-term potentiation (LTP). Additionally, 
ANS1B has been found to regulate endothelial barrier function and 
permeability [35]. SV2B (synaptic vesicle glycoprotein 2B) is a mediator 
of synaptic vesicle transport and exocytosis, and an increase in SV2B 
expression has previously been tied to behavioral improvements in mice 
following environmental enrichment [36]. SYGP1 (Ras/RTP GTPase 
activating protein) regulates the trafficking of α-amino-3--
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to the 
cell membrane, and therefore plays a critical role in regulating neuronal 
plasticity, synaptic function, and cognition [37,38]. Together, these 
findings suggest that dabigatran treatment may increase neuronal 
function at the synapse and promote improved plasticity and learning 
potential. 
When viewing these results, it is important to recognize that dabi-
gatran may exert beneficial effects by mechanisms other than direct 
inhibition of thrombin-receptor-mediated pathways. Thrombin activity 
drives the formation of fibrin, and fibrin has been identified as a po-
tential pathological mediator in AD [39]. Anti-coagulant proteins, such 
as activated protein C (APC), act in opposition to thrombin [40] and 
promote anti-inflammatory processes through differential activation of 
the same receptor [41,42]. This may, in part, help to explain the acti-
vation of protective MAPK signaling processes following dabigatran 
treatment. This is supported by the finding that dabigatran treatment 
significantly increased ANT3 (antithrombin III), a natural thrombin in-
hibitor (Fig. 4A). 
These findings represent preliminary data from a short-term pilot 
study, as such must be interpreted with a degree of caution. While the 
expression of both iNOS and NOX4 were significantly decreased with 
dabigatran treatment, further analysis of enzymatic activity may be 
required to better understand the anti-oxidant effect of dabigatran. 
Furthermore, in some cases, as in NOX4, dabigatran significantly alters 
the impact of a marker that is not significantly changed from wild type to 
Tg4510 mouse. Without dabigatran treatment in the wild type animals, 
we cannot definitively state whether the positive effects of dabigatran 
treatment displayed are specific to the Tg4510 model. Future investi-
gation of the therapeutic benefits of dabigatran treatment should 
Table 2 
List of proteins and corresponding abbreviations. Proteins of interest were 
identified, classified, and categorized based on previous literature. Proteins were 
obtained from UniProt and data obtained by LC-MS/MS with SWATH acquisi-
tion were analyzed in Skyline.  
Pathway Abbreviation Full Protein Name 
Alzheimer’s 
Disease 
A4 Amyloid-beta A4 protein (APP) 
ACTN2 Alpha-actinin-2 
ANS1B Ankyrin repeat and sterile alpha motif 
domain-containing protein 1B (Amyloid-beta 
protein intracellular domain-associated 
protein 1) 
APOE Apolipoprotein E (Apo-E) 
BACE1 Beta-secretase 1 
BACE2 Beta-secretase 2 
G3BP2 Ras GTPase-activating protein-binding 
protein 2 
G6PD1 Glucose-6-phosphate 1-dehydrogenase X 
GNAZ Guanine nucleotide-binding protein G(z) 
subunit alpha 
HPCA Neuron-specific calcium-binding protein 
hippocalcin 
KCC2A Calcium/calmodulin-dependent protein 
kinase type II subunit alpha 
NAC2 Sodium/calcium exchanger 2 
NCKP1 Nck-associated protein 1 
PACN1 Protein kinase C and casein kinase substrate in 
neurons protein 1 (Syndapin-1) 
Q8CFX3 Protocadherin 1 
SV2B Synaptic vesicle glycoprotein 2B 
SYGP1 Ras/Rap GTPase-activating protein SynGAP 
TAU 
(Human) 
Microtubule-associated protein tau 
TAU (Mouse) Microtubule-associated protein tau 
TAU (Total) Microtubule-associated protein tau 
TBB3 Tubulin beta-3 chain 
TLN1 Talin-1 




CDK5 Cyclin-dependent-like kinase 5 
DYN1 Dynamin-1 
MK01 Mitogen-activated protein kinase 1 
MK03 Mitogen-activated protein kinase 3 
MK08 Mitogen-activated protein kinase 8 
MK09 Mitogen-activated protein kinase 9 
MP2K1 Dual specificity mitogen-activated protein 
kinase kinase 1 
MP2K2 Dual specificity mitogen-activated protein 
kinase kinase 2 
KPCA Protein kinase C alpha type 
KPCB Protein kinase C beta type 
KPCD Protein kinase C delta type 
RACK1 Receptor of activated protein C kinase 1 
ROCK1 Rho-associated protein kinase 1 




FA5 Coagulation factor V (Activated protein C 
cofactor) 
FA8 Coagulation factor VIII (Procoagulant 
component) 
FA10 Coagulation factor X 
FIBA Fibrinogen alpha chain 
FIBB Fibrinogen beta chain 
ITAL Integrin alpha-L 
ITAM Integrin alpha-M 
ITAV Integrin alpha-V 
ITB2 Integrin beta-2 




COX2 Cytochrome c oxidase subunit 2 
DLG4 Disks large homolog 4 
GFAP Glial fibrillary acidic protein (GFAP) 
ICAM1 Intercellular adhesion molecule 1 
ICAM5 Intercellular adhesion molecule 5 
MILK2 MICAL-like protein 2 
NFKB1 Nuclear factor NF-kappa-B p105 subunit 
NOS3 Nitric oxide synthase, endothelial  
Table 2 (continued ) 
Pathway Abbreviation Full Protein Name 
PARK7 Protein/nucleic acid deglycase DJ-1 
PTPRC Receptor-type tyrosine-protein phosphatase C 
TLR4 Toll-like receptor 4 
VCAM1 Vascular cell adhesion protein 1  
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Fig. 3. Proteomic expression differences between wild type mice, Tg-Vehicle, and Tg-Dabigatran mice are detected by LC-MS/MS SWATH analysis. (A) 
Volcano plot of data sets from brain homogenates of wild type mice and Tg4510 mice (Tg-Vehicle). (B) Volcano plot of data sets from brain homogenates of Tg4510 
mice (Tg-Vehicle) and Tg4510 mice treated with dabigatran (Tg-Dabigatran). 
Fig. 4. Treatment of Tg4510 mice with dabigatran 
causes widespread differences in protein expres-
sion. Proteomic expression differences between wild 
type mice, Tg4510 mice (Tg-Vehicle), and Tg4510 
mice treated with dabigatran (Tg-Dabigatran) are 
detected by LC-MS/MS SWATH analysis. Functional 
categories of proteins that show significant expression 
differences are shown as follows: (A) coagulation 
cascade, (B) cell signaling, and (C) inflammation- 
related. Mean ± SEM (n = 5), statistical differences 
determined by multiple t-tests, *p ≤ 0.05 vs. Wild 
Type, #p ≤ 0.05 vs. Tg-Vehicle.   
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include these relevant control groups, in order to better understand the 
context in which dabigatran exerts its effects. 
Studies in both animal models and human populations utilizing 
anticoagulant therapies support the notion that mediators of the coag-
ulation cascade may promote AD pathology. A recent study showed that 
treatment of TgCRND8 transgenic AD mice with dabigatran improved 
spatial memory deficits and reduced neuroinflammation and amyloid 
plaque formation [19]. In that study, animals were two months-of-age at 
the start of the study and received drug treatment for one year. In the 
current study, we explored the possible acute effects of dabigatran on an 
older population with established disease. Our results suggest that even 
a short intervention in older animals produces benefits, as demonstrated 
by the reduction in oxidative stress and AD markers we document. 
Future studies are needed to further define the beneficial effects of 
dabigatran over an extended time course and in additional transgenic 
models of AD. Our pilot study in a tau-based mouse model adds 
important information to a growing body of data implicating thrombin 
inhibition as a therapeutic strategy in AD. An open-label study of a 
hirudin (natural antithrombin anticoagulant) compound in 84 patients 
with mild-to-moderate AD found that hirudin plus donepezil reduced 
the rate of cognitive decline compared to donepezil alone, suggesting 
that direct thrombin inhibition may indeed be an effective strategy for 
treating this neurodegenerative disease [43]. In a longitudinal, 
community-based study, use of dabigatran was associated with a lower 
risk of new-onset dementia compared to warfarin [44]. Along with our 
data, these studies demonstrate that targeting thrombin could be 
beneficial in AD and that thrombin inhibitors could play a role in a drug 
treatment regimen for AD. 
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